Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.…
Here's Why Coherus Oncology (CHRS) Is a Great 'Buy the Bottom' Stock Now
Coherus Oncology (NASDAQ: CHRS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 145 employees.
The shares were at 0.3698 USD on 20 November 2026, down 72.4% over 52 weeks. Its 52-week range is 0.3628 USD to 2.616 USD: the price is 85.9% below the high and 1.9% above the low.
Its market capitalisation is 57.15M USD.
Coherus Oncology reports return on equity of 275.4%, an operating margin of -271.1% and revenue up 23.4% year over year.
It holds more cash than debt, a net cash position of 14.08M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 8 March 2027.